Excited to share my PhD work in the @PittetLab, published today in @CellCellPress! We show that immunotherapy can expand a distinct interferon-responsive neutrophil state that contributes to successful responses to therapy: https://t.co/IOys2yN0AP
❔What is special about an immune system that successfully attacks tumors, compared to one that doesn’t?
Our new study in @CellCellPress led by @jgungabeesoon, @Nich and @Mate_Kiss_ aimed to address this question. A joint work with the great @KleinLabHMS
https://t.co/Mhi4A7QdfR
📢 Research Alert! 🧬🔬 🩺 We are super excited that our latest study, led by the great @RubenBill5 & Asa Wirapati, is out: https://t.co/94ScYEro0h
We set out to shed some light on the tumor microenvironment and its impact on cancer progression.
🧵
SPOTLIGHT: @BBS_Harvard@PittetLab@jgungabeesoon demonstrated that neutrophils exhibit remarkable plasticity and could acquire an antitumor phenotype in response to immunotherapy. https://t.co/BwckDFV1Yq
The Garris Lab @MGHCSB @MGH_RI @harvardmed is looking for curious and driven postdoctoral fellows who want to investigate the biology of #dendriticcells in cancer growth and therapy. Interested candidates should send their CV and cover letter to [email protected]
1/ 🤩Whoah! I'm so excited to be a part of this awesome @MempelThorsten study, led by @DiPilato and colleagues. It shows a mechanism by which "good" cells (i.e. antitumor CD8 T cells) can survive in tumors to do their job.
https://t.co/N2T3zGKiUR
The intrepid Mauro (now @DiPilatoLab) and team did it again: CXCR6 enables CTL to control tumors by guiding their interactions with CCR7+ cDC in perivascular survival niches of the tumor stroma. Thanks to our fantastic collaborators. See 🧵 for details.
https://t.co/wgXGmqw5Xy
Immune networks within the glial cell ecosystem maintain brain health.
Our latest is out today in @nature. Astrocytic interleukin-3 programs microglia and limits Alzheimer’s disease.
This was a wonderful collaboration with @RudyTanzi and his team. 1/
https://t.co/Bl1nPkk9MA
Are brain borders the new bone marrow?
New work from the @mzhlab complements recent findings from the @TheColonnaLab and @jonykipnis labs to show brain-dedicated B-lymphopoiesis!
A pleasure to contribute our little grain
https://t.co/9DJAQzsKSo
It’s out! My PhD work focusing on toxicities associated with anti-cancer immunotherapy drugs:
https://t.co/05zFhK2wNS
And my first #tweetorial brought to you by @PittetLab where you can learn all about our findings! https://t.co/SlsX9GH9Wj
A new @MGH_RI, @harvardmed study pinpoints a potential target to offset adverse effects from #cancer#immunotherapy, revealing in mice that obstructing inflammatory neutrophils in the liver prevented the toxicity of anti-CD40 agonist therapy: https://t.co/Foih0gnooM
👉Macrophages & neutrophils may drive toxicities after #immunotherapy, but NOT dendritic cells. Instead, dendritic cells, incl. DC3 (also called, LAMP3 DC, mregDC) may be key for antitumor immunity. This could be important for next gen treatments.
https://t.co/fcq1a0Y2Td
0/ Published today in Science Immunology! Work from our lab investigating immunotherapy-driven toxicities (immune related adverse events, a.k.a. irAEs), which are a major clinical problem in cancer immunotherapy clinics. #tweetorial
https://t.co/GEl2peGJGX
Pleased to announce my latest study @RockefellerUniv published in @ScienceTM. https://t.co/xktTomFpYy In this study we provide proof of concept for bladder infused CD40 agonistic antibodies as a local treatment for bladder cancer.
Low-carb, high-fat diets—including the popular “ketogenic” diet—may not be any more effective at keeping obesity at bay than those that balance calorie intake with energy expenditure, a new #SciencePerspective suggests. https://t.co/xWIe3Ffxsk #WeekendReads
👉The @PittetLab is hiring a #bioinformatician to pursue our work on the tumor immune microenvironment.
All this in an amazing place https://t.co/X8Kvja4gMS 🇨🇭... and with a great bioinformatics network @KleinLabHMS@carmonation !
Please share or let us know if interested!